JP2011116755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011116755A5 JP2011116755A5 JP2010253326A JP2010253326A JP2011116755A5 JP 2011116755 A5 JP2011116755 A5 JP 2011116755A5 JP 2010253326 A JP2010253326 A JP 2010253326A JP 2010253326 A JP2010253326 A JP 2010253326A JP 2011116755 A5 JP2011116755 A5 JP 2011116755A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- cancer
- inhibitor
- specifically binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 18
- 229940022399 cancer vaccine Drugs 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 108020004999 messenger RNA Proteins 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45103903P | 2003-02-28 | 2003-02-28 | |
| US60/451,039 | 2003-02-28 | ||
| US48214303P | 2003-06-24 | 2003-06-24 | |
| US60/482,143 | 2003-06-24 | ||
| US53170403P | 2003-12-22 | 2003-12-22 | |
| US60/531,704 | 2003-12-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508934A Division JP2006523226A (ja) | 2003-02-28 | 2004-03-01 | Ｔ細胞調節方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013217056A Division JP2014058523A (ja) | 2003-02-28 | 2013-10-18 | Ｔ細胞調節方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011116755A JP2011116755A (ja) | 2011-06-16 |
| JP2011116755A5 true JP2011116755A5 (https=) | 2012-02-09 |
Family
ID=32966451
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508934A Withdrawn JP2006523226A (ja) | 2003-02-28 | 2004-03-01 | Ｔ細胞調節方法 |
| JP2010253326A Withdrawn JP2011116755A (ja) | 2003-02-28 | 2010-11-12 | Ｔ細胞調節方法 |
| JP2013217056A Withdrawn JP2014058523A (ja) | 2003-02-28 | 2013-10-18 | Ｔ細胞調節方法 |
| JP2016080113A Withdrawn JP2016169216A (ja) | 2003-02-28 | 2016-04-13 | Ｔ細胞調節方法 |
| JP2017142742A Expired - Lifetime JP6758259B2 (ja) | 2003-02-28 | 2017-07-24 | Ｔ細胞調節方法 |
| JP2019072698A Withdrawn JP2019135247A (ja) | 2003-02-28 | 2019-04-05 | Ｔ細胞調節方法 |
| JP2021214040A Pending JP2022034067A (ja) | 2003-02-28 | 2021-12-28 | Ｔ細胞調節方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508934A Withdrawn JP2006523226A (ja) | 2003-02-28 | 2004-03-01 | Ｔ細胞調節方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013217056A Withdrawn JP2014058523A (ja) | 2003-02-28 | 2013-10-18 | Ｔ細胞調節方法 |
| JP2016080113A Withdrawn JP2016169216A (ja) | 2003-02-28 | 2016-04-13 | Ｔ細胞調節方法 |
| JP2017142742A Expired - Lifetime JP6758259B2 (ja) | 2003-02-28 | 2017-07-24 | Ｔ細胞調節方法 |
| JP2019072698A Withdrawn JP2019135247A (ja) | 2003-02-28 | 2019-04-05 | Ｔ細胞調節方法 |
| JP2021214040A Pending JP2022034067A (ja) | 2003-02-28 | 2021-12-28 | Ｔ細胞調節方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (8) | US20060240024A1 (https=) |
| EP (4) | EP1897548B2 (https=) |
| JP (7) | JP2006523226A (https=) |
| AU (1) | AU2004217526B2 (https=) |
| CA (1) | CA2517287C (https=) |
| CY (1) | CY1114755T1 (https=) |
| DK (1) | DK1897548T4 (https=) |
| ES (1) | ES2439580T5 (https=) |
| FI (1) | FI1897548T4 (https=) |
| PL (1) | PL1897548T5 (https=) |
| PT (1) | PT1897548E (https=) |
| SI (1) | SI1897548T2 (https=) |
| WO (1) | WO2004078928A2 (https=) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI1897548T4 (fi) | 2003-02-28 | 2024-09-03 | The Johns Hopkins University | T-solujen säätely |
| US20080085261A1 (en) * | 2004-10-19 | 2008-04-10 | Haynes Barton F | Vaccine Adjuvant |
| SI1928492T1 (sl) * | 2005-09-01 | 2011-09-30 | Celgene Corp | Imunoloĺ ka uporaba imunomodulatornih spojin za cepivo in protiinfekcijsko bolezensko terapijo |
| US20090317407A1 (en) * | 2006-05-02 | 2009-12-24 | Lacelle Michael G | Augmentation of immune response to cancer vaccine |
| WO2008126940A1 (ja) * | 2007-04-10 | 2008-10-23 | The University Of Tokyo | 新規ｔ細胞 |
| EP1987839A1 (en) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US20110059471A1 (en) * | 2008-03-14 | 2011-03-10 | Medinet Co., Ltd. | Antibody having an immune-enhancement function |
| CN102046780A (zh) * | 2008-03-27 | 2011-05-04 | 宝生物工程株式会社 | 转染的细胞的生产方法 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010062966A2 (en) * | 2008-11-26 | 2010-06-03 | The General Hospital Corporation | Methods for inducing mixed chimerism |
| MY180616A (en) | 2011-06-30 | 2020-12-03 | Genzyme Corp | Inhibitors of t-cell activation |
| US20140303134A1 (en) * | 2011-10-26 | 2014-10-09 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| WO2014116730A2 (en) | 2013-01-23 | 2014-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized hepatitis b core polypeptide |
| EA037554B1 (ru) | 2013-03-15 | 2021-04-13 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Анти-lag-3 связывающие белки |
| WO2014144666A2 (en) * | 2013-03-15 | 2014-09-18 | The University Of Chicago | Methods and compositions related to t-cell activity |
| SG11201601763SA (en) | 2013-09-20 | 2016-04-28 | Bristol Myers Squibb Co | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| JP2017500313A (ja) * | 2013-12-09 | 2017-01-05 | ブレット バイオテクノロジー， インコーポレーテッドＢｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 特異的ウイルス様粒子−ＣｐＧオリゴヌクレオチドワクチンおよびその使用 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| US20170165364A1 (en) * | 2014-02-21 | 2017-06-15 | Idac Theranostics, Inc. | Therapeutic agent for solid cancer |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| SG10201912986PA (en) | 2014-05-28 | 2020-02-27 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| JP6991857B2 (ja) | 2014-10-10 | 2022-01-13 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療 |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| TWI702290B (zh) * | 2015-04-07 | 2020-08-21 | 富禾生醫股份有限公司 | 經修飾之自然殺手ｔ細胞、醫藥組合物及其用途 |
| EA039293B1 (ru) * | 2015-06-05 | 2021-12-30 | Мерк Шарп И Доум Корп. | Антитела против lag3 и антигенсвязывающие фрагменты |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| WO2017004252A1 (en) | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
| US12577289B2 (en) | 2015-06-30 | 2026-03-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Surrogate co-receptors for t cells and methods of use |
| KR20180029238A (ko) | 2015-07-15 | 2018-03-20 | 피어이스 파마슈티컬즈 게엠베하 | Lag-3에 특이적인 신규 단백질 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| EP3328377A4 (en) * | 2015-07-31 | 2019-03-13 | Tarveda Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES |
| KR20250073532A (ko) | 2015-09-02 | 2025-05-27 | 이뮤텝 에스.에이.에스. | 항-lag-3 항체 |
| NZ739090A (en) | 2015-10-02 | 2025-06-27 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| SG11201803409UA (en) | 2015-11-20 | 2018-05-30 | Regeneron Pharma | Non-human animals having a humanized lymphocyte-activation gene 3 |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| KR20180086502A (ko) | 2015-12-16 | 2018-07-31 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항원-결합 단편 |
| CN109310885B (zh) | 2016-03-15 | 2022-05-31 | 梅尔莎纳医疗公司 | NaPi2b靶向抗体-药物缀合物及其使用方法 |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| CA3024359A1 (en) | 2016-06-23 | 2017-12-28 | Jiangsu Hengrui Medicine Co., Ltd. | Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof |
| RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| EA039718B1 (ru) * | 2016-07-21 | 2022-03-03 | Регенерон Фармасьютикалз, Инк. | Антитела к lag3 и их применения |
| AU2017325272A1 (en) * | 2016-09-08 | 2019-04-04 | Daiichi Sankyo Company, Limited | Antibody for treating autoimmune diseases |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| CN108070613B (zh) | 2016-11-11 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018086583A1 (en) * | 2016-11-11 | 2018-05-17 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric lag-3 |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| WO2018134274A1 (en) | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3 |
| CA3053348A1 (en) | 2017-02-10 | 2018-08-16 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| TW201834697A (zh) | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Her2標靶抗體－藥物結合物之組合療法 |
| RU2761377C2 (ru) | 2017-04-03 | 2021-12-07 | Ф. Хоффманн-Ля Рош Аг | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 |
| TWI690538B (zh) | 2017-04-05 | 2020-04-11 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
| SI3606954T1 (sl) | 2017-04-05 | 2022-10-28 | F. Hoffmann - La Roche Ag | Protitelesa proti LAG3 |
| EP3630179A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
| SMT202300418T1 (it) | 2017-05-30 | 2024-01-10 | Bristol Myers Squibb Co | Trattamento di tumori positivi per lag-3 |
| CN110996974A (zh) * | 2017-06-16 | 2020-04-10 | 梅约医学教育与研究基金会 | 增加免疫应答的材料和方法 |
| WO2019011306A1 (en) * | 2017-07-13 | 2019-01-17 | Nanjing Leads Biolabs Co., Ltd. | LAG-3 BINDING ANTIBODIES AND USES THEREOF |
| EP3717021A1 (en) | 2017-11-27 | 2020-10-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| EP3727463A1 (en) | 2017-12-21 | 2020-10-28 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| RU2771384C2 (ru) | 2017-12-22 | 2022-05-04 | Цзянсу Хэнжуй Медсин Ко., Лтд. | Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение |
| US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
| US20200354457A1 (en) | 2018-01-31 | 2020-11-12 | Hoffmann-La Roche Inc. | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
| AU2019369340A1 (en) | 2018-10-29 | 2021-05-20 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| CN111304247B (zh) | 2018-12-20 | 2021-03-16 | 百奥赛图江苏基因生物技术有限公司 | 人源化lag-3基因改造动物模型的制备方法及应用 |
| CN109666699B (zh) * | 2018-12-29 | 2023-02-28 | 杭州科兴生物科技有限公司 | 一种基于lag-3/mhc ii阻断功能及其生物效应的药物快速筛选方法 |
| EP3956465A4 (en) * | 2019-04-16 | 2023-04-05 | Regents of the University of Minnesota | Biomarker for transplantation tolerance induced by apoptotic donor leukocytes |
| SG11202111262XA (en) | 2019-05-13 | 2021-11-29 | Regeneron Pharma | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| CN111415707B (zh) * | 2020-03-10 | 2023-04-25 | 四川大学 | 临床个体化肿瘤新抗原的预测方法 |
| CN114605544B (zh) * | 2020-06-05 | 2023-08-01 | 北京天广实生物技术股份有限公司 | Lag3抗体及其用途 |
| WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| JP2022176672A (ja) * | 2021-05-17 | 2022-11-30 | 国立大学法人北海道大学 | ペプチド及び医薬用組成物 |
| WO2022245816A1 (en) * | 2021-05-18 | 2022-11-24 | Pelican Therapeutics, Inc. | Treatment of autoimmune inflammatory diseases with tnfrsf25-binding agents |
| WO2024192033A1 (en) | 2023-03-13 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma |
| WO2025106736A2 (en) | 2023-11-15 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
| US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
| US4658957A (en) * | 1985-01-28 | 1987-04-21 | Abbott Laboratories | Utility tray |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| FR2656800B1 (fr) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5976877A (en) * | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
| ES2281899T3 (es) | 1994-05-06 | 2007-10-01 | Institut Gustave Roussy | Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica; anticuerpo anti-idiotipo. |
| AU701375B2 (en) * | 1995-07-21 | 1999-01-28 | Institut Gustave Roussy | Methods for detecting, identifying, isolating, and selectively labelling and targeting Th1 lymphocytes by means of the LAG-3 protein |
| IL125884A0 (en) | 1996-03-04 | 1999-04-11 | Targeted Genetics Corp | Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes |
| ATE476496T1 (de) * | 1996-03-04 | 2010-08-15 | Calyx Bio Ventures Inc | Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten |
| US6482925B1 (en) * | 1996-11-28 | 2002-11-19 | Applied Research Systems Ars Holding N.V. | Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants |
| JP3920928B2 (ja) * | 1996-11-29 | 2007-05-30 | アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ | 移植片拒絶反応の防止法および普遍的遺伝子治療宿主細胞の生産法 |
| CN1196786C (zh) * | 1996-11-29 | 2005-04-13 | 应用研究系统Ars股份公司 | 抗移植排斥细胞及其用途 |
| EP0900841A1 (en) * | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
| EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
| JPH1164707A (ja) * | 1997-08-13 | 1999-03-05 | Fuji Photo Optical Co Ltd | ズームレンズ鏡筒 |
| US6432925B1 (en) * | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
| GB0007088D0 (en) * | 2000-03-23 | 2000-05-17 | Torsana A S | Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates |
| IL158860A0 (en) | 2001-05-15 | 2004-05-12 | Agensys Inc | Nucleic acids and corresponding proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer and pharmaceutical compositions containing the same |
| CA2448320A1 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Ribozyme based treatment of female reproductive diseases |
| JP4460282B2 (ja) * | 2001-06-12 | 2010-05-12 | バイエル・クロップサイエンス・アーゲー | 高アミロースデンプンを合成するトランスジェニック植物 |
| ES2386775T3 (es) * | 2001-07-23 | 2012-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos |
| FI1897548T4 (fi) | 2003-02-28 | 2024-09-03 | The Johns Hopkins University | T-solujen säätely |
| CN102558352A (zh) | 2003-06-27 | 2012-07-11 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| TWI580694B (zh) * | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
-
2004
- 2004-03-01 FI FIEP07021595.9T patent/FI1897548T4/fi active
- 2004-03-01 EP EP07021595.9A patent/EP1897548B2/en not_active Expired - Lifetime
- 2004-03-01 PT PT70215959T patent/PT1897548E/pt unknown
- 2004-03-01 EP EP20130179162 patent/EP2659893A3/en not_active Withdrawn
- 2004-03-01 AU AU2004217526A patent/AU2004217526B2/en not_active Expired
- 2004-03-01 US US10/547,371 patent/US20060240024A1/en not_active Abandoned
- 2004-03-01 WO PCT/US2004/006133 patent/WO2004078928A2/en not_active Ceased
- 2004-03-01 DK DK07021595.9T patent/DK1897548T4/da active
- 2004-03-01 SI SI200432110T patent/SI1897548T2/sl unknown
- 2004-03-01 ES ES07021595T patent/ES2439580T5/es not_active Expired - Lifetime
- 2004-03-01 JP JP2006508934A patent/JP2006523226A/ja not_active Withdrawn
- 2004-03-01 EP EP18177034.8A patent/EP3427741A3/en not_active Withdrawn
- 2004-03-01 CA CA2517287A patent/CA2517287C/en not_active Expired - Lifetime
- 2004-03-01 EP EP04716126A patent/EP1596871A4/en not_active Withdrawn
- 2004-03-01 PL PL07021595.9T patent/PL1897548T5/pl unknown
-
2009
- 2009-10-22 US US12/578,887 patent/US8551481B2/en not_active Expired - Fee Related
-
2010
- 2010-11-12 JP JP2010253326A patent/JP2011116755A/ja not_active Withdrawn
-
2012
- 2012-11-16 US US13/679,485 patent/US9005629B2/en not_active Expired - Lifetime
-
2013
- 2013-10-18 JP JP2013217056A patent/JP2014058523A/ja not_active Withdrawn
- 2013-11-14 CY CY20131101011T patent/CY1114755T1/el unknown
- 2013-12-13 US US14/105,293 patent/US20140127226A1/en not_active Abandoned
-
2015
- 2015-12-18 US US14/973,806 patent/US10787513B2/en active Active
-
2016
- 2016-04-13 JP JP2016080113A patent/JP2016169216A/ja not_active Withdrawn
-
2017
- 2017-07-24 JP JP2017142742A patent/JP6758259B2/ja not_active Expired - Lifetime
-
2018
- 2018-03-30 US US15/942,168 patent/US10934354B2/en not_active Expired - Fee Related
-
2019
- 2019-04-05 JP JP2019072698A patent/JP2019135247A/ja not_active Withdrawn
-
2021
- 2021-01-22 US US17/155,228 patent/US20210230275A1/en not_active Abandoned
- 2021-12-28 JP JP2021214040A patent/JP2022034067A/ja active Pending
-
2023
- 2023-06-06 US US18/206,552 patent/US20240174747A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011116755A5 (https=) | ||
| Schinkel et al. | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview | |
| Jung et al. | The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo | |
| ZA202106265B (en) | Compositions and methods for inhibiting gene expression of lpa | |
| WO2014022739A3 (en) | Modified rnai agents | |
| JP7266534B2 (ja) | 天然化合物および線維症 | |
| MX373926B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| CL2014003637A1 (es) | Anticuerpo monoclonal optimizado que se une al gen 3 de activación de linfocitos (lag-3); molécula biespecífica que lo comprende; inmunoconjugado que comprende el anticuerpo unido a un agente terapéutico; composición; ácido nucleico; vector; célula huésped; método de preparación; y uso para inhibir el crecimiento de un tumor o tratar una infección viral. | |
| EA201290712A1 (ru) | Альфа-излучающие комплексы | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| UA115517C2 (uk) | Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b | |
| UA117072C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським | |
| NZ606988A (en) | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia | |
| Bahreyni et al. | Synergistic viro-chemoimmunotherapy in breast cancer enabled by bioengineered immunostimulatory exosomes and dual-targeted coxsackievirus B3 | |
| JP2014523398A5 (https=) | ||
| BR112013002738A2 (pt) | métodos e compostos para o diagnóstico e o tratamento do câncer | |
| BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
| BR112013000779A2 (pt) | composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial | |
| Kim et al. | A small molecule, 4-phenylbutyric acid, suppresses HCV replication via epigenetically induced hepatic hepcidin | |
| Liu et al. | ShRNA-mediated silencing of the Ndc80 gene suppress cell proliferation and affected hepatitis B virus-related hepatocellular carcinoma | |
| Xiao et al. | Inhibition of microRNA-429 attenuates oxygen–glucose deprivation/reoxygenation-induced neuronal injury by promoting expression of GATA-binding protein 4 | |
| RU2015139515A (ru) | Комбинированное лечение | |
| Tang et al. | Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy | |
| EA201391327A1 (ru) | Терапевтическое лечение |